On April 27, 2026 HCW Biologics Inc. (the "Company" or "HCW Biologics"), (NASDAQ: HCWB), a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation reported major development regarding its tetra-valent, second-generation T-Cell Engager Program (the "Big BiTE") based on its TRBC platform technology, was presented at the poster session at the American Association of Cancer Research ("AACR") Annual Meeting 2026, which took place from April 17 – 22, 2026 in San Diego, California.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
HCW11-018b, the lead candidate of the "Big BiTE" program, is a tetra-valent T-cell engager designed to enhance anti-tumor activities and tolerability to treat a wide spectrum of solid tumors. The Company’s preclinical data showed HCW11-018b could significantly shrink well-established tumors and prevent cancer metastasis in xenograft animal models with broad coverage for human solid tumor indications.
The new data in the poster has revealed the mechanism of action that drives these results. HCW11-018b utilizes Cis-binding (or cis-interaction) to regulate immune cell reactivity that masks the receptors which prevent trans-binding and inhibit membrane flexibility. The data showed that HCW11-018b is only activated within the tumor microenvironment, which is expected to increase the efficacy and tolerability of this tetra-valent T Cell Engager against human tumor cells.
Dr. Hing C. Wong, the Company’s Founder and Chief Executive Officer, stated, "HCW11-018b exhibits remarkable anti-tumor activities with high tolerability in animal models. With its streamlined GMP manufacturing process, the Company is vigorously -pursuing the clinical development path for solid tumors with particular focus on pancreatic and ovarian cancer. The IND application is projected to be filed in the first half of 2027."
The poster, entitled, "An innovative approach to improve bispecific T-cell engagers for solid tumor therapy," was presented by Dr. Wong at the AACR (Free AACR Whitepaper) Annual Meeting 2026. The poster is available on the Company’s investors’ website in the following link: View Source
(Press release, HCW Biologics, APR 27, 2026, View Source [SID1234664834])